Claims
- 1. A pharmaceutical composition comprising a recombinant human HVEM polypeptide, wherein said polypeptide is encoded by a cDNA contained within the plasmid pBEC580, designated as ATCC No. 97236, and a physiologically acceptable diluent.
- 2. The pharmaceutical composition of claim 1, wherein said HVEM polypeptide comprises amino acids 1-185 of human HVEM.
- 3. The pharmaceutical composition of claim 1, wherein said HVEM polypeptide is soluble.
- 4. The pharmaceutical composition of claim 3, wherein said soluble HVEM polypeptide does not comprise a rabbit immunoglobulin heavy chain amino acid sequence.
- 5. The pharmaceutical composition of claim 1, wherein said cDNA is the sequence of SEQ ID NO:1 from nucleotide position 294 to nucleotide position 1142.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/333,279, which is a divisional of U.S. application Ser. No. 08/509,024, filed on Jul. 28, 1995, both of which are herein incorporated by reference in their entireties.
GOVERNMENT SUPPORT
[0002] This invention was make in part using funds obtained from the U.S. Government (National Institutes of Health Grant Nos. RO1 AI36293 and F32HI09022) and the U.S. Government may have certain rights in the invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08509024 |
Jul 1995 |
US |
Child |
09333279 |
Jun 1999 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09924231 |
Aug 2001 |
US |
Child |
10745718 |
Dec 2003 |
US |
Parent |
09333279 |
Jun 1999 |
US |
Child |
09924231 |
Aug 2001 |
US |